Antivirus Treatment for Patients with Hepatitis C Cirrhosis at Decompensated Stage after Elimination of Complication
- VernacularTitle:失代偿期丙肝肝硬化患者并发症消除后的抗病毒治疗
- Author:
Yongrui YANG
;
Hui LI
;
Ling SHEN
;
Yaling WANG
- Publication Type:Journal Article
- Keywords:
Hepatitis C;
Chronic;
Liver cirrhosis;
Hapetitis/Complication;
Peg-IFNα-2a
- From:
Journal of Kunming Medical University
2014;(1):56-58,67
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy of antiviral therapy of pegylated interferon (Peg-IFN) α-2a combined with ribavirin for patients with hepatitis C cirrhosis and hypersplenism underwent splenectomy or partial splenic embolization. Methods Thirty-eight patients with hepatitis C cirrhosis (genotype Ⅰ HCV infection) hypersplenism failed to the anti-viral therapy were performed splenectomy or partial splenic embolization to improving hypersplenism. After 3 months,Peg-IFNα-2a 90μg or 135 μg was given subcutaneously once weekly, plus ribavirin 600-1 000 mg/d orally for 1 year of the treatment. During the treatment, patients were followed at four-week intervals, and then followed-up every month until the 24th week after stopping. Liver function, blood routine, renal function, HCV RNA, and adverse reaction of medication were observed during treatment and the follow-up period. Results Splenic function of patients with hepatitis C cirrhosis and hypersplenism was improved after hypersplenism splenectomy or partial splenic embolization. The sustained virologic response (SVR) rate was 63.88%after giving Peg-IFNα-2a combined with ribavirin anti-viral treatment. Conclusion After splenectomy or partial splenic embolization, patients with hepatitis C cirrhosis and hypersplenism showed the better SVR at the treatment of Peg-IFNα-2a combined with ribavirin. The treatment could delay the progress of the hepatitis C cirrhosis and reduce the incidence of liver failure and liver cancer.
